SLC1A3 and diabetic retinopathy: The NOX2 inhibitor GLX7013170 increased BCL-2 levels and augmented the expression of excitatory amino acid transporter 1 (EAAT1) in the retina of a diabetic retinopathy animal model, restoring glutamate metabolism and suppressing excitotoxicity and neuronal apoptosis [157].